| Host |
Mouse |
| Klon |
2B11/PD7-26 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil or lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ + IgG1 /κ |
| Verdünnung |
PD7/26/16: human peripheral blood lymphocytes maintained in T cell growth factor. 2B11: isolated neoplastic cells from T cell lymphoma |
| Lokalisation |
Cell membrane |
CD45RB (LCA)
|
Zeta Corporation |
2B11/PD7-26 |
0.1 ml |
Concentrate |
CE/IVD |
Z2093MT |
-
|
| Host |
Mouse |
| Klon |
UCHL-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Cell Membrane |
CD45RO
|
Diagnostic Biosystems |
UCHL-1 |
1 ml |
Concentrate |
CE/IVD |
MOB043 |
-
|
| Host |
Mouse |
| Klon |
UCHL-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Cell Membrane |
CD45RO
|
Diagnostic Biosystems |
UCHL-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB043-01 |
-
|
| Host |
Mouse |
| Klon |
UCHL-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Cell Membrane |
CD45RO
|
Diagnostic Biosystems |
UCHL-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB043-05 |
-
|
| Host |
Mouse |
| Klon |
UCHL-1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Cell Membrane |
CD45RO
|
Diagnostic Biosystems |
UCHL-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM015 |
-
|
| Host |
Mouse |
| Klon |
TS2/7 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Mouse IgG1 |
CD49a (Integrin alpha1)
|
Zytomed Systems GmbH |
TS2/7 |
200 µg |
Purified |
RUO |
603-1115 |
-
|
| Host |
Rat |
| Klon |
YTH34.5 |
| Format |
Purified |
| Methode |
F, P, FL |
| Vorbehandlung |
optional: Trypsin or Pronase |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:20 (P) |
| Isotyp |
Rat IgG2b |
CD52 (CAMPATH 1)
|
Zytomed Systems GmbH |
YTH34.5 |
20 µg (20 µl) |
Purified |
RUO |
603-2225 |
-
|
| Host |
Rat |
| Klon |
YTH34.5 |
| Format |
Purified |
| Methode |
F, P, FL, EL, IP, WB |
| Vorbehandlung |
optional: Trypsin or Pronase |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:20 - 1:40 (P) |
| Isotyp |
Rat IgG2b |
CD52 (CAMPATH 1)
|
Zytomed Systems GmbH |
YTH34.5 |
0.2 mg (200 µl) |
Purified |
RUO |
603-2226 |
-
|
| Host |
Mouse |
| Klon |
15.2 |
| Format |
Purified |
| Methode |
F, P, IP, FL |
| Positivkontrolle |
Human Tonsil |
| Verdünnung |
1:50 -1:100 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human monocytes |
CD54 (I-CAM-1)
|
Zytomed Systems GmbH |
15.2 |
100 µg |
Purified |
RUO |
603-1211 |
-
|
| Host |
Mouse |
| Klon |
15.2 |
| Format |
Purified |
| Methode |
F, P, FL |
| Positivkontrolle |
Human Tonsil |
| Verdünnung |
1:50 -1:100 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human monocytes |
CD54 (I-CAM-1)
|
Zytomed Systems GmbH |
15.2 |
20 µg |
Purified |
RUO |
603-1212 |
-
|
| Host |
Mouse |
| Klon |
123C3.D5 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Neuroblastom |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Membrane preparation of a small cell lung carcinoma |
| Lokalisation |
Cell Membrane |
CD56
|
Diagnostic Biosystems |
123C3.D5 |
1 ml |
Concentrate |
CE/IVD |
MOB261 |
-
|
| Host |
Mouse |
| Klon |
123C3.D5 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Neuroblastom |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Membrane preparation of a small cell lung carcinoma |
| Lokalisation |
Cell Membrane |
CD56
|
Diagnostic Biosystems |
123C3.D5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB261-01 |
-
|
| Host |
Mouse |
| Klon |
123C3.D5 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Neuroblastom |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Membrane preparation of a small cell lung carcinoma |
| Lokalisation |
Cell Membrane |
CD56
|
Diagnostic Biosystems |
123C3.D5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB261-05 |
-
|
| Host |
Mouse |
| Klon |
123C3.D5 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Neuroblastom |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Membrane preparation of a small cell lung carcinoma |
| Lokalisation |
Cell Membrane |
CD56
|
Diagnostic Biosystems |
123C3.D5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM110 |
-
|
| Host |
Mouse |
| Klon |
123C3.D5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Neuroblastoma, neuroendocrine carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Membrane preparation of a small cell lung carcinoma |
| Lokalisation |
Cell membrane |
CD56
|
Zeta Corporation |
123C3.D5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2038ML |
-
|
| Host |
Mouse |
| Klon |
123C3.D5 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Neuroblastoma, neuroendocrine carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Membrane preparation of a small cell lung carcinoma |
| Lokalisation |
Cell membrane |
CD56
|
Zeta Corporation |
123C3.D5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2038MP |
-
|
| Host |
Mouse |
| Klon |
123C3.D5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Neuroblastoma, neuroendocrine carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Membrane preparation of a small cell lung carcinoma |
| Lokalisation |
Cell membrane |
CD56
|
Zeta Corporation |
123C3.D5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2038MS |
-
|
| Host |
Mouse |
| Klon |
123C3.D5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Neuroblastoma, neuroendocrine carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Membrane preparation of a small cell lung carcinoma |
| Lokalisation |
Cell membrane |
CD56
|
Zeta Corporation |
123C3.D5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2038MT |
-
|
| Host |
Mouse |
| Klon |
NK-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
CD57
|
Diagnostic Biosystems |
NK-1 |
1 ml |
Concentrate |
CE/IVD |
MOB163 |
-
|
| Host |
Mouse |
| Klon |
NK-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
CD57
|
Diagnostic Biosystems |
NK-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB163-01 |
-
|
| Host |
Mouse |
| Klon |
NK-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
CD57
|
Diagnostic Biosystems |
NK-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB163-05 |
-
|
| Host |
Mouse |
| Klon |
NK-1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
CD57
|
Diagnostic Biosystems |
NK-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM130 |
-
|
| Host |
Mouse |
| Klon |
NK-1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph node or tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgM |
| Verdünnung |
Human peripheral blood mononuclear cells |
| Lokalisation |
Cell membrane |
CD57
|
Zeta Corporation |
NK-1 |
1ml |
Concentrate |
CE/IVD |
Z2111ML |
-
|
| Host |
Mouse |
| Klon |
NK-1 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph node or tonsil. |
| Verdünnung |
- |
| Isotyp |
IgM |
| Verdünnung |
Human peripheral blood mononuclear cells |
| Lokalisation |
Cell membrane |
CD57
|
Zeta Corporation |
NK-1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2111MP |
-
|
| Host |
Mouse |
| Klon |
NK-1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph node or tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgM |
| Verdünnung |
Human peripheral blood mononuclear cells |
| Lokalisation |
Cell membrane |
CD57
|
Zeta Corporation |
NK-1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2111MS |
-
|
| Host |
Mouse |
| Klon |
NK-1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph node or tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgM |
| Verdünnung |
Human peripheral blood mononuclear cells |
| Lokalisation |
Cell membrane |
CD57
|
Zeta Corporation |
NK-1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2111MT |
-
|
| Host |
Mouse |
| Klon |
MEM-43 |
| Format |
Purified |
| Methode |
F, P, EL, WB, FL, IP |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Isotyp |
Mouse IgG2a |
CD59
|
Zytomed Systems GmbH |
MEM-43 |
200 µg |
Purified |
RUO |
603-1254 |
-
|
| Host |
Rat |
| Klon |
YTH53.1 |
| Format |
Purified |
| Methode |
F, WB, FL |
| Isotyp |
Rat IgG2b |
| Verdünnung |
Human peripheral blood T cells |
CD59
|
Zytomed Systems GmbH |
YTH53.1 |
200 µg |
Purified |
RUO |
603-1259 |
-
|
| Host |
Mouse |
| Klon |
Y2/51 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate or Fast Enzyme (optional) |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD61
|
Diagnostic Biosystems |
Y2/51 |
1 ml |
Concentrate |
CE/IVD |
MOB164 |
-
|
| Host |
Mouse |
| Klon |
Y2/51 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate or Fast Enzyme (optional) |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD61
|
Diagnostic Biosystems |
Y2/51 |
0.1 ml |
Concentrate |
CE/IVD |
MOB164-01 |
-
|
| Host |
Mouse |
| Klon |
Y2/51 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate or Fast Enzyme (optional) |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD61
|
Diagnostic Biosystems |
Y2/51 |
0.5 ml |
Concentrate |
CE/IVD |
MOB164-05 |
-
|
| Host |
Mouse |
| Klon |
Y2/51 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate or Fast Enzyme (optional) |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD61
|
Diagnostic Biosystems |
Y2/51 |
6 ml |
Ready-to-use |
CE/IVD |
PDM064 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM33 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Bone marrow or tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human ITGB3 protein fragment (aa 385-490) |
| Lokalisation |
Cell membrane/Cytoplasm |
CD61
|
Zeta Corporation |
ZM33 |
1 ml |
Concentrate |
CE/IVD |
Z2337ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM33 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Bone marrow or tonsil. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human ITGB3 protein fragment (aa 385-490) |
| Lokalisation |
Cell membrane/Cytoplasm |
CD61
|
Zeta Corporation |
ZM33 |
7 ml |
Ready-to-use |
CE/IVD |
Z2337MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM33 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Bone marrow or tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human ITGB3 protein fragment (aa 385-490) |
| Lokalisation |
Cell membrane/Cytoplasm |
CD61
|
Zeta Corporation |
ZM33 |
0.5 ml |
Concentrate |
CE/IVD |
Z2337MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM33 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Bone marrow or tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human ITGB3 protein fragment (aa 385-490) |
| Lokalisation |
Cell membrane/Cytoplasm |
CD61
|
Zeta Corporation |
ZM33 |
0.1 ml |
Concentrate |
CE/IVD |
Z2337MT |
-
|
| Host |
Mouse |
| Klon |
Y2/51 |
| Format |
Purified |
| Methode |
FL, F, P |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
PHA stimulated peripheral blood cells |
CD61 (Integrin beta3)
|
Zytomed Systems GmbH |
Y2/51 |
100 µg |
Purified |
RUO |
603-2368 |
-
|
| Host |
Mouse |
| Klon |
Y2/51 |
| Format |
Purified |
| Methode |
FL, F, P, WB |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
PHA stimulated peripheral blood cells |
CD61 (Integrin beta3)
|
Zytomed Systems GmbH |
Y2/51 |
200 µg |
Purified |
RUO |
603-2369 |
-
|
| Host |
Mouse |
| Klon |
AK-6 |
| Format |
Purified |
| Methode |
F, P, WB, FL |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:500 - 1:2000 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human platelet membrane glycoproteins |
CD62 (P-Selectin)
|
Zytomed Systems GmbH |
AK-6 |
200 µg |
Purified |
RUO |
603-1286 |
-
|
| Host |
Mouse |
| Klon |
AK-6 |
| Format |
Purified |
| Methode |
FL, F, P, IF, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:500 - 1:2000 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human platelet membrane glycoproteins |
CD62 (P-Selectin)
|
Zytomed Systems GmbH |
AK-6 |
100 µg |
Purified |
RUO |
603-1287 |
-
|
| Host |
Mouse |
| Klon |
CL2/6 |
| Format |
Purified |
| Methode |
F, FL, IF |
| Isotyp |
Mouse IgG2a |
CD62E (E-Selectin)
|
Zytomed Systems GmbH |
CL2/6 |
100 µg |
Purified |
RUO |
603-1294 |
-
|
| Host |
Mouse |
| Klon |
1.2B6 |
| Format |
Purified |
| Methode |
FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human E-Selectin (ELAM-1) |
CD62E /CD62P - FITC
|
Zytomed Systems GmbH |
1.2B6 |
100 µg |
Purified |
RUO |
603-1298C |
-
|
| Host |
Mouse |
| Klon |
NK-I/C3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
CD63
|
Diagnostic Biosystems |
NK-I/C3 |
1 ml |
Concentrate |
CE/IVD |
MOB301 |
-
|
| Host |
Mouse |
| Klon |
NK-I/C3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
CD63
|
Diagnostic Biosystems |
NK-I/C3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB301-01 |
-
|
| Host |
Mouse |
| Klon |
NK-I/C3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
CD63
|
Diagnostic Biosystems |
NK-I/C3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB301-05 |
-
|
| Host |
Mouse |
| Klon |
80H3 |
| Format |
Purified |
| Methode |
F, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
CML leukocytes |
CD66b
|
Zytomed Systems GmbH |
80H3 |
200 µg |
Purified |
RUO |
603-1320 |
-
|
| Host |
Rabbit |
| Klon |
SP251 |
| Format |
Concentrate |
| Methode |
P, FL |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Verdünnung |
Synthetic peptide within Human CD68 aa 100-200 (internal sequence) |
| Lokalisation |
Cytoplasmic membrane |
CD68
|
Zytomed Systems GmbH |
SP251 |
1 ml |
Concentrate |
RUO |
503-5514 |
-
|
| Host |
Mouse |
| Klon |
PG-M1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Fast Enzyme or other Enzymes |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:40 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD68
|
Diagnostic Biosystems |
PG-M1 |
1 ml |
Concentrate |
CE/IVD |
MOB094 |
-
|
| Host |
Mouse |
| Klon |
PG-M1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Fast Enzyme or other Enzymes |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:40 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD68
|
Diagnostic Biosystems |
PG-M1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB094-01 |
-
|
| Host |
Mouse |
| Klon |
PG-M1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Fast Enzyme or other Enzymes |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:40 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD68
|
Diagnostic Biosystems |
PG-M1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB094-05 |
-
|